Trametinib-d4 is the deuterated form of Trametinib. Trametinib (GSK1120212, JTP-74057) is an orally bioavailable MEK inhibitor, effectively inhibiting MEK1 and MEK2 with an IC50 of 2 nM. Additionally, Trametinib can activate autophagy and induce apoptosis.
Target:
Autophagy|||Apoptosis|||MEK
* VAT and and shipping costs not included. Errors and price changes excepted
